The FDA approved application BLA761497, an insulin aspart product carrying the suffix -fsan, on 15 September 2026. The applicant is Emerge Bioscience Pte Ltd.
The four-letter suffix is the naming convention the FDA applies to biological products, and insulins have been regulated as biologics in the United States since 2020. A new licence for a rapid-acting analogue is a supply and pricing event rather than a clinical one: the molecule is one prescribers already know.
The database entry records the approval and nothing more - no interchangeability designation appears in it, and interchangeability is what determines whether a pharmacist may substitute without the prescriber. For Indian practice the position is unchanged; a US licence says nothing about CDSCO, and there is no indication this product has been filed here.
- Rapid-acting insulin analogue; no new molecule and no new indication.
- A US biologic licence does not permit pharmacy substitution unless interchangeability is separately designated.
- The record does not state an interchangeability designation either way.
- No CDSCO position is known, so nothing changes for prescribing in India.
- Check the brand actually dispensed if a patient reports a change in insulin packaging.
Why it matters
More licensed aspart products means more substitution at the pharmacy counter, and patients notice device and packaging changes before clinicians hear about them.
Don't overread it
This is a licence approval, not a safety finding and not a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free